Physician

Syed Shariq Ahmad Saghir, M.D

According to 2025 Medicare claims, Syed Saghir, M.D (NPI: 1841319498) practices nephrology in the Sherman-Denison, TX market, with the plurality of this provider's patient population coming from Grayson, TX. This provider's primary affiliated billing organization is MEDICAL ASSOCIATES OF TEXAS, PA (NPI: 1548663651; TIN: 461908917) and primary practice location at 75092-7069. Saghir is affiliated with the UT Southwestern Accountable Care Network (ACO ID: D0211), participating under the REACH model.

Saghir's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,417 traditional Medicare patients, billed 10,224 HCPCS/CPT codes, and received $804,792 in Medicare payments. The top billing code was 99223 (Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes). Part D data shows 1,553 prescription claims across 254 beneficiaries totaling $110,027 in drug costs, led by Lokelma (Sodium Zirconium Cyclosilicate). 2018 DME data shows 38 claims. Open Payments data shows 21 records totaling $139,297. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $194,659 to $804,792. In contrast, Part D prescription costs have declined steadily, from $219,293 to $110,027. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	534	3,173	$194,659
2016	630	2,471	$196,108
2017	960	6,033	$431,481
2018	1,228	7,071	$544,718
2019	1,216	7,460	$635,006
2020	1,110	7,827	$655,250
2021	1,110	8,883	$770,598
2022	1,195	9,948	$842,197
2023	1,069	8,810	$769,103
2024	1,417	10,224	$804,792

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	133	901	$219,293
2016	183	1,723	$306,661
2017	271	2,768	$146,500
2018	279	2,151	$633,330
2019	256	2,094	$108,707
2020	211	1,536	$202,852
2021	208	1,273	$93,148
2022	229	1,225	$72,406
2023	241	1,370	$92,616
2024	254	1,553	$110,027

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	31	$1,169
2017	22	185	$4,554
2018	N/R	38	$673
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99223	Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes	324	359	$120
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	171	804	$87
99233	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes	1,013	2,975	$82
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	566	2,788	$55
99490	Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month	150	1,065	$43

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lokelma	Sodium Zirconium Cyclosilicate	41	1,311	$34,227
Rayaldee	Calcifediol	14	420	$16,911
Veltassa	Patiromer Calcium Sorbitex	12	438	$14,633
Farxiga	Dapagliflozin Propanediol	15	750	$14,604
Nifedipine Er	Nifedipine	152	12,165	$5,021

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	11	$211	OPKO Pharmaceuticals, LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	10	$139,086	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Syed Shariq Ahmad Saghir, M.D?

Tedicare shows public-source Medicare data for Syed Shariq Ahmad Saghir, M.D (NPI 1841319498), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Syed Shariq Ahmad Saghir, M.D have ACO affiliation data?

Syed Shariq Ahmad Saghir, M.D is shown with ACO affiliation data for UT Southwestern Accountable Care Network (REACH, ACO ID D0211).

What billing organization is linked to Syed Shariq Ahmad Saghir, M.D?

Syed Shariq Ahmad Saghir, M.D is linked to MEDICAL ASSOCIATES OF TEXAS, PA (billing NPI 1548663651) in the available physician profile data.

Does Syed Shariq Ahmad Saghir, M.D have Open Payments data?

Syed Shariq Ahmad Saghir, M.D has 21 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.